home About Us People Portfolio News Contact Us Fund II Investor Login » Fund III Investor Login » Fund IV Investor Login »

Avinger Inc.

$45 million

Medical Device

Avinger Announces Presentations by Key Opinion Leaders and Live Case Transmission at LINC »

Avinger Announces Closing of $7.6 Million Registered Direct Offering »

Avinger Announces 510(k) Clearance for Lightbox 3 Next-Generation Imaging Console »

Avinger Announces 510(k) Filing for New Lightbox 3 Imaging Console »

Avinger Announces 510(k) Filing for New Pantheris In-Stent Restenosis Indication »

Avinger Announces Issuance and Allowance of Seven U.S. Patents »

New Publications Highlight Clinical Benefits of Avinger PAD Therapies »

Avinger Provides Update on Tigereye(TM) Commercial Launch »

Avinger Expands Tigereye(TM) Limited Launch »

Avinger Receives Nasdaq Extension, Recommends Stockholders Vote FOR All Proxy Proposals »

Avinger Receives FDA Clearance of Ocelaris Next Generation Image-guided CTO Crossing System »

Avinger Closes $3.15 Million Equity Offering »

Avinger, Inc. Announces Closing of Public Offering of Common Stock and Underwriters’ Full Exercise of Option to Purchase Additional Shares »

Avinger, Inc. Announces Drawdown of $10 Million Under Term Loan Facility with CRG »

Avinger Announces Filing of 510(k) Application for Enhanced Version of Pantheris(TM) »

Avinger Successfully Completes VISION IDE Trial for Pantheris(TM) »

Avinger, Inc. Receives FDA 510(k) Clearance for Pantheris(TM) »

Avinger, Inc. Secures Up To $55M in Financing from CRG »

-- Financing to Support Commercial Launch of Pantheris™ --

Redwood City, California, September 23, 2015 – Avinger, Inc., (NASDAQ: AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, announced today that it has entered into a term loan agreement and a securities purchase agreement with CRG (formerly Capital Royalty L.P.).  The agreements provide Avinger with new financing of up to $55.0 million.
Under the terms of the term loan agreement, Avinger initially borrowed $30.0 million, which requires only interest payments for four years. Concurrent with this first tranche, CRG purchased $5.0 million in shares of the Company’s common stock at a price of $14.357 per share. Avinger has the option under the term loan agreement to borrow an additional $20.0 million, in two tranches of $10.0 million each, at its discretion upon achieving certain milestones.
Avinger plans to use proceeds from the financing to retire existing debt, fund post-marketing clinical trials and begin broad-scale commercialization of the Pantheris image-guided atherectomy device in 2016. Avinger recently filed a submission with the U.S. Food and Drug Administration (FDA) for 510(k) clearance to market Pantheris for the treatment of patients with PAD.
“We are pleased to support Avinger in achieving its growth plans and believe that the Company’s lumivascular technology will translate into significantly improved treatment for PAD patients,” said Charles Tate, Chairman of CRG. “The demonstrated clinical value of the Pantheris device gives us the confidence to invest in Avinger’s business model.”
“We are delighted to have the confidence and support of CRG, an investment partner renowned for its strategic investments in healthcare,” said Jeff Soinski, President and CEO of Avinger. “Avinger is in a unique and exciting position today as we move towards commercialization of Pantheris early next year. This loan facility not only provides us with greater financial flexibility in the future, but is an important step in our ability to bring the benefits of lumivascular technology to PAD patients.”
Armentum Partners acted as a financial advisor to Avinger for the transaction.
About Avinger, Inc.
Avinger, Inc. is a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems for the treatment of patients with peripheral arterial disease (PAD). PAD is characterized by a build-up of plaque in the arteries that supply blood to the arms and legs. The Company’s mission is to dramatically improve the treatment of vascular disease through the introduction of products based on its lumivascular platform, the only intravascular image-guided system available in this market. Avinger’s current lumivascular products include the Lightbox™ imaging console and Ocelot™ family of catheters, which are designed to penetrate total arterial blockages, known as chronic total occlusions, or CTOs. The Company is also developing Pantheris™, an image-guided atherectomy device, designed to precisely remove arterial plaque in PAD patients. For more information, please visit the Company's website at www.avinger.com.

About CRG
Founded in 2003, CRG (previously known as Capital Royalty L.P.) is a healthcare-focused investment firm with over $2 billion of assets under management that provides capital to healthcare companies primarily through structured debt and senior secured loans. CRG works across the spectrum of life science products and technologies and targets investment sizes ranging between $20 million and $200 million. The firm partners with commercial-stage healthcare companies to provide flexible financing solutions so they can achieve their growth objectives. CRG is headquartered in Houston, Texas with offices in Boulder, Colorado and New York City. For additional information, please visit www.crglp.com.

# # #

Avinger Contact:
Leigh Salvo
(415) 513-1281
Email: ir@avinger.com

CRG Contact:
Luke Düster
Managing Director
(713) 209-7361
Email: lduster@crglp.com